Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF THE SENATE

00 AUG 11 PH 1:35

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name	
Swidler Berlin Shereff Friedman, LLF	
2. Address Check if different than previously reported	
3. Principal Place of Business (If different from line 2)	
City: Washington State/	Zip (or Country) D.C. 20007
4. Contact Name Telephone	E-mail (optional) 5. Senate ID#
Lester Hyman (202) 424-750	37460-606
7. Client Name Self	6. House ID#
Transkaryotic Therapies, Inc.	31419059
TYPE OF REPORT 8. Year 2000 Midyear 9. Check if this filing amends a previously filed version of this	
.10. Check if this is a Termination Report □	Date 11. No Lobbying Activity C
INCOME OR EXPENSES - Complete Either	r Line 12 OR Line 13
12. Leabying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 🖸	Less than 510,000 🗅
\$10,000 or more 🖾 🜣 \$ 60,000	\$\\\\0,000 or more \bigsim \infty \\$ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Provide a good faith estimate, rounded to the nearest \$20,000,	
of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	Method A. Reporting amounts using LDA definitions only
activities on behalf of the client).	Method B. Reporting amounts under section 6033(b)(8)of the internal Revenue Code
	Method C. Reporting amounts under section 162(e) of the internal Revenue Code
Signature (east)	
Printed Name and Title Lester Kyman, Partner	
LD-2 (REV. 6/98)	PAGE For 2

Registrant Name	Swidler Berlin Shereff Friedwan, LLP	Client Name Transkaryotic Therapies, Inc.	
engaged in lobby	TIVITY. Select as many codes a ring on behalf of the client during quested. Attach additional page(	as necessary to reflect the general issue areas in which the registrant the reporting period. Using a separate page for each code, provide s) as needed.	
15. General issu	e area code (one po	er page)	
16. Specific lobb	bying issues		
Legislati Appropria	on affecting drug patents tion bills affecting phar	, drug pricing and bioproduct tax credits; maceutical industry (e.g., H.R. 4461, S. 2536)	
17. House(s) of	Congress and Federal agencies co	ontacted	
U.S. Sena	e of Representatives te Office of the President		
18. Name of ea	ch individual who acted as a lobb	yist in this issue area	ı
	Name	Covered Official Position (if applicable)	Nev
Brian Fit	zgerald		
Barry Dir	enfeld		
Keith Col	e		a
Gary Gall			O
Lester My	man		a
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Q.
,,,,,, ISC-137-137-137-137-137-137-13	The state of the s	1 2 V W. I tompoor	
			Ф
			E .
19. Interest of c	ach foreign cauty in the specific issue	is listed on line 16 above	ם
19. Interest of ea	ach foreign entity in the specific issue	es listed on line 16 above	ם
19. Interest of each of the state of the sta	ach foreign entity in the specific issue	cs listed on line 16 above	ם
(	Cestis Pf-	7/21/00	ם